ArticleClinical endoscopy2021
The Clinical and Metabolic Effects of Intragastric Balloon on Morbid Obesity and Its Related Comorbidities.
Article in Clinical endoscopy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study.Obesity surgery · 2025Trial
- Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity.Clinical endoscopy · 2024Review
- Evaluating Weight Loss Efficacy in Obesity Treatment with Allurion's Ingestible Gastric Balloon: A Retrospective Study Utilizing the Scale App Health Tracker.Clinics and practice · 2024Article
- Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control.Clinical endoscopy · 2024Review
- Endoscopic Bariatric Therapy for Obesity and Metabolic Syndrome.The Korean journal of helicobacter and upper gastrointestinal research · 2023Review
- Overview on the endoscopic treatment for obesity: A review.World journal of gastroenterology · 2023Review
- How effective is intragastric balloon insertion as an obesity treatment in Korea?Clinical endoscopy · 2023Article
- Efficacy and safety of intragastric balloon for obesity in Korea.Clinical endoscopy · 2023Article
- Status of bariatric endoscopy-what does the surgeon need to know? A review.World journal of gastrointestinal surgery · 2022Article
- Various Novel and Emerging Technologies in Endoscopic Bariatric and Metabolic Treatments.Clinical endoscopy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is becoming increasingly prevalent worldwide, and its metabolic sequelae lead to a significant burden on healthcare resources. Options for the management of obesity include lifestyle modification, pharmacological treatment, surgery, and endoscopic bariatric therapies (EBTs). Among these, EBTs are more effective than diet and lifestyle modification and are less invasive than bariatric surgery. In recent years, there have been significant advances in technologies pertaining to EBTs. Of all the available EBTs, there is a significant amount of clinical experience and published data regarding intragastric balloons (IGBs) because of their comparatively long development period. Currently, the United States Food and Drug Administration (FDA) has approved three IGBs, including Orbera (Apollo Endosurgery, Austin, TX, USA), ReShape Duo (ReShape Medical, San Clemente, CA, USA), and Obalon (Obalon Therapeutics, Carlsbad, CA, USA). The aim of this review is to summarize the available literature on the efficacy of IGBs in weight loss and their impact on obesity-related metabolic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.